[go: up one dir, main page]

RU2019107788A - Анти-her2 конъюгат антитела с лекарственным средством - Google Patents

Анти-her2 конъюгат антитела с лекарственным средством Download PDF

Info

Publication number
RU2019107788A
RU2019107788A RU2019107788A RU2019107788A RU2019107788A RU 2019107788 A RU2019107788 A RU 2019107788A RU 2019107788 A RU2019107788 A RU 2019107788A RU 2019107788 A RU2019107788 A RU 2019107788A RU 2019107788 A RU2019107788 A RU 2019107788A
Authority
RU
Russia
Prior art keywords
ggfg
maleimide
amino acid
drug
antibody
Prior art date
Application number
RU2019107788A
Other languages
English (en)
Other versions
RU2794183C2 (ru
Inventor
Хиройуки НАИТО
Юсуке ОГИТАНИ
Такеси МАСУДА
Такаси НАКАДА
Масао ЙОСИДА
Синдзи АСИДА
Кодзи МОРИТА
Хидеки МИЯЗАКИ
Юдзи КАСУЯ
Итиро ХАЯКАВА
Юки АБЕ
Original Assignee
Дайити Санкио Компани, Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53756672&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2019107788(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Дайити Санкио Компани, Лимитед filed Critical Дайити Санкио Компани, Лимитед
Publication of RU2019107788A publication Critical patent/RU2019107788A/ru
Application granted granted Critical
Publication of RU2794183C2 publication Critical patent/RU2794183C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68037—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a camptothecin [CPT] or derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6857—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from lung cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6859—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from liver or pancreas cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6869—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3023—Lung
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Claims (70)

1. Способ получения конъюгата антитела с лекарственным средством, включающий взаимодействие соединения, представленного следующей формулой:
(малеимид-N-ил)-(CH2)n3-C(=O)-L2-LP-NH-(CH2)n1-La-(CH2)n2-C(=O)-(NH-DX)
с анти-HER2 антителом или его реакционно-способным производным, и конъюгирование группы линкер-лекарственное средство с антителом, способом, с образованием тиоэфирной связи на участке дисульфидных связей, представленных в шарнирной части антитела,
где
n1 является целым числом от 0 до 6,
n2 является целым числом от 0 до 5,
n3 является целым числом от 2 8,
L2 представляет собой -NH-(CH2CH2-O)n4-CH2CH2-C(=O)- или одинарную связь,
где n4 является целым числом от 1 до 6,
LP представляет собой пептидный остаток, состоящий из от 2 до 7 аминокислот, выбранных из фенилаланина, глицина, валина, лизина, цитруллина, серина, глутаминовой кислоты и аспарагиновой кислоты,
La представляет собой -O- или одинарную связь, и
(малеимид-N-ил)- представляет собой группу, представленную следующей формулой:
Figure 00000001
где атом азота находится в связующем положении, и
-(NH-DX) представляет собой группу, представленную следующей формулой:
Figure 00000002
где атом азота аминогруппы в положении 1 находится в связующем положении.
2. Способ по п.1, где LP представляет собой тетрапептидный остаток -GGFG-.
3. Способ по п.1, где соединение является соединением, выбранным из следующей группы:
(малеимид-N-ил)-CH2CH2-C(=O)-GGFG-NH-CH2CH2-C(=O)-(NH-DX),
(малеимид-N-ил)-CH2CH2-C(=O)-GGFG-NH-CH2CH2CH2-C(=O)-(NH-DX),
(малеимид-N-ил)-CH2CH2CH2CH2CH2-C(=O)-GGFG-NH-CH2CH2-C(=O)-(NH-DX),
(малеимид-N-ил)-CH2CH2CH2CH2CH2-C(=O)-GGFG-NH-CH2CH2CH2-C(=O)-(NH-DX),
(малеимид-N-ил)-CH2CH2CH2CH2CH2-C(=O)-GGFG-NH-CH2CH2CH2CH2CH2-C(=O)-(NH-DX),
(малеимид-N-ил)-CH2CH2CH2CH2CH2-C(=O)-GGFG-NH-CH2-O-CH2-C(=O)-(NH-DX),
(малеимид-N-ил)-CH2CH2CH2CH2CH2-C(=O)-GGFG-NH-CH2CH2-O-CH2-C(=O)-(NH-DX),
(малеимид-N-ил)-CH2CH2-C(=O)-NH-CH2CH2-O-CH2CH2-O-CH2CH2-C(=O)-GGFG-NH-CH2CH2-C(=O)-(NH-DX),
(малеимид-N-ил)-CH2CH2-C(=O)-NH-CH2CH2-O-CH2CH2-O-CH2CH2-C(=O)-GGFG-NH-CH2CH2CH2-C(=O)-(NH-DX),
(малеимид-N-ил)-CH2CH2-C(=O)-NH-CH2CH2-O-CH2CH2-O-CH2CH2-O-CH2CH2-O-CH2CH2-C(=O)-GGFG-NH-CH2CH2-C(=O)-(NH-DX), и
(малеимид-N-ил)-CH2CH2-C(=O)-NH-CH2CH2-O-CH2CH2-O-CH2CH2-O-CH2CH2-O-CH2CH2-C(=O)-GGFG-NH-CH2CH2CH2-C(=O)-(NH-DX).
4. Способ по п.3, где соединение является соединением, выбранным из следующей группы:
(малеимид-N-ил)-CH2CH2CH2CH2CH2-C(=O)-GGFG-NH-CH2-O-CH2-C(=O)-(NH-DX),
(малеимид-N-ил)-CH2CH2CH2CH2CH2-C(=O)-GGFG-NH-CH2CH2-O-CH2-C(=O)-(NH-DX), и
(малеимид-N-ил)-CH2CH2-C(=O)-NH-CH2CH2-O-CH2CH2-O-CH2CH2-C(=O)-GGFG-NH-CH2CH2CH2-C(=O)-(NH-DX).
5. Способ по п.4, где соединение представляет собой:
(малеимид-N-ил)-CH2CH2CH2CH2CH2-C(=O)-GGFG-NH-CH2-O-CH2-C(=O)-(NH-DX).
6. Способ по п.4, где структурная группа линкер-лекарственное средство представляет собой:
(малеимид-N-ил)-CH2CH2CH2CH2CH2-C(=O)-GGFG-NH-CH2CH2-O-CH2-C(=O)-(NH-DX).
7. Способ по п.4, где структурная группа линкер-лекарственное средство представляет собой:
(малеимид-N-ил)-CH2CH2-C(=O)-NH-CH2CH2-O-CH2CH2-O-CH2CH2-C(=O)-GGFG-NH-CH2CH2CH2-C(=O)-(NH-DX).
8. Способ по п.1, где конъюгат антитела с лекарственным средством содержит структуру линкер-лекарственное средство, представленную следующей формулой:
-(cукцинимид-3-ил-N)-(CH2)n3-C(=O)-L2-LP-NH-(CH2)n1-La-(CH2)n2-C(=O)-(NH-DX),
которая конъюгирована с анти-HER2 антителом через тиоэфирную связь, образованную на участке дисульфидных связей, представленных в шарнирной части анти-HER2 антитела.
9. Способ по п.5, где конъюгат антитела с лекарственным средством содержит структуру линкер-лекарственное средство, представленную следующей формулой:
-(cукцинимид-3-ил-N)-CH2CH2CH2CH2CH2-C(=O)-GGFG-NH-CH2-O-CH2-C(=O)-(NH-DX),
которая конъюгирована с анти-HER2 антителом через тиоэфирную связь, образованную на участке дисульфидных связей, представленных в шарнирной части анти-HER2 антитела.
10. Способ по п.6, где конъюгат антитела с лекарственным средством содержит структуру линкер-лекарственное средство, представленную следующей формулой:
-(cукцинимид-3-ил-N)-CH2CH2CH2CH2CH2-C(=O)-GGFG-NH-CH2CH2-O-CH2-C(=O)-(NH-DX),
которая конъюгирована с анти-HER2 антителом через тиоэфирную связь, образованную на участке дисульфидных связей, представленных в шарнирной части анти-HER2 антитела.
11. Способ по п.7, где конъюгат антитела с лекарственным средством содержит структуру линкер-лекарственное средство, представленную следующей формулой:
-(cукцинимид-3-ил-N)-CH2CH2-C(=O)-NH-CH2CH2-O-CH2CH2-O-CH2CH2-C(=O)-GGFG-NH-CH2CH2CH2-C(=O)-(NH-DX),
которая конъюгирована с анти-HER2 антителом через тиоэфирную связь, образованную на участке дисульфидных связей, представленных в шарнирной части анти-HER2 антитела.
12. Способ по любому из пп. 1-11, где анти-HER2 антитело содержит тяжелую цепь, состоящую из аминокислотной последовательности, состоящей из остатков аминокислот 1-449 последовательности SEQ ID NO: 1, и легкую цепь, состоящую из аминокислотной последовательности, представленной как SEQ ID NO: 2.
13. Способ по любому из пп. 1-11, где анти-HER2 антитело содержит тяжелую цепь, состоящую из аминокислотной последовательности, представленной как SEQ ID NO: 1, и легкую цепь, состоящую из аминокислотной последовательности, представленной как SEQ ID NO: 2.
14. Способ по любому из пп. 1-11, где среднее количество структурных единиц выбранных конъюгированных структур линкер-лекарственное средство на одно антитело составляет от 2 до 8.
15. Способ по любому из пп. 1-11, где среднее количество структурных единиц выбранных конъюгированных структур линкер-лекарственное средство на одно антитело составляет от 3 до 8.
16. Способ получения конъюгат антитела с лекарственным средством, представленного следующей формулой:
Figure 00000003
где n представляет среднее количество структурных единиц конъюгированных структур линкер-лекарственное средство на одно анти-HER2 антитело,
и где анти-HER2 антитело содержит:
тяжелую цепь, состоящую из аминокислотной последовательности, состоящей из остатков аминокислот 1-449 последовательности SEQ ID NO: 1, и аминокислотной последовательности легкой цепи, состоящую из остатков аминокислот 1-214 последовательности SEQ ID NO: 2, или
аминокислотную последовательность тяжелой цепи, состоящую из последовательности SEQ ID NO: 1, и легкую цепь, состоящую из аминокислотной последовательности SEQ ID NO: 2,
и где способ включает стадии:
обработки анти-HER2 антитела в восстанавливающих условиях, а затем
взаимодействия анти-HER2 антитела с соединением, представленным следующей формулой:
Figure 00000004
.
17. Способ по п.16, где аминокислотная последовательность тяжелой цепи анти-HER2 антитела состоит из остатков аминокислот 1-449 последовательности SEQ ID NO: 1, и аминокислотная последовательность легкой цепи анти-HER2 антитела состоит из остатков аминокислот 1-214 последовательности SEQ ID NO: 2.
18. Способ по п.16, где аминокислотная последовательность тяжелой цепи анти-HER2 антитела состоит из аминокислотной последовательности SEQ ID NO: 1, и аминокислотная последовательность легкой цепи анти-HER2 антитела состоит из аминокислотной последовательности SEQ ID NO: 2.
19. Способ по любому из пп. 16-18, где значение n находится в диапазоне от 2 до 8.
20. Способ по любому из пп. 16-18, где значение n находится в диапазоне от 3 до 8.
RU2019107788A 2014-01-31 2015-01-28 Анти-her2 конъюгат антитела с лекарственным средством RU2794183C2 (ru)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
JP2014017777 2014-01-31
JP2014-017777 2014-01-31
JP2014168944 2014-08-22
JP2014-168944 2014-08-22
JP2014-227886 2014-11-10
JP2014227886 2014-11-10

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU2016123597A Division RU2683780C3 (ru) 2015-01-28 Анти-her2 конъюгат антитела с лекарственным средством

Publications (2)

Publication Number Publication Date
RU2019107788A true RU2019107788A (ru) 2019-05-17
RU2794183C2 RU2794183C2 (ru) 2023-04-12

Family

ID=

Also Published As

Publication number Publication date
SG10201800210TA (en) 2018-02-27
KR20210088745A (ko) 2021-07-14
TWI789700B (zh) 2023-01-11
ES2727351T3 (es) 2019-10-15
FI4212552T3 (fi) 2025-01-31
PL3466976T3 (pl) 2021-12-20
KR101916553B1 (ko) 2018-11-07
KR20220100994A (ko) 2022-07-18
JP2022180504A (ja) 2022-12-06
RU2016123597A (ru) 2018-03-02
CY1124774T1 (el) 2022-11-25
BR112016013482A2 (ru) 2017-10-03
JP7703727B2 (ja) 2025-07-07
TW201613649A (en) 2016-04-16
US11795236B2 (en) 2023-10-24
CN110464847A (zh) 2019-11-19
NO2021027I1 (no) 2021-07-06
SI4212552T1 (sl) 2025-03-31
EP3466976A1 (en) 2019-04-10
AU2020200596A1 (en) 2020-02-20
PT3466976T (pt) 2021-10-27
IL278891B2 (en) 2024-06-01
PH12016500904B1 (en) 2016-07-11
KR102417312B1 (ko) 2022-07-05
JP7467557B2 (ja) 2024-04-15
JP6914380B2 (ja) 2021-08-04
HUS2100025I1 (hu) 2021-07-28
DK3466976T3 (da) 2021-12-13
TW202500196A (zh) 2025-01-01
US11584800B2 (en) 2023-02-21
JP6466895B2 (ja) 2019-02-06
AU2020200596B2 (en) 2022-03-03
FR21C1030I1 (ru) 2021-08-27
IL278891A (en) 2021-01-31
DK3101032T3 (en) 2019-04-29
AU2015212265B2 (en) 2020-01-02
TWI796243B (zh) 2023-03-11
ES3005311T3 (en) 2025-03-14
BR112016013482B1 (pt) 2022-04-19
EP4464707A3 (en) 2025-04-02
KR102606930B1 (ko) 2023-11-29
TW201834692A (zh) 2018-10-01
RS58415B1 (sr) 2019-04-30
FR21C1030I2 (fr) 2022-04-08
PH12020552271A1 (en) 2022-05-02
TW202237115A (zh) 2022-10-01
KR102881140B1 (ko) 2025-11-04
IL245252A0 (en) 2016-06-30
US20240026030A1 (en) 2024-01-25
KR102238848B1 (ko) 2021-04-09
KR20230162159A (ko) 2023-11-28
RU2016123597A3 (ru) 2018-10-12
CY1121573T1 (el) 2020-05-29
KR102465042B1 (ko) 2022-11-09
IL245252B (en) 2019-06-30
JP2017105789A (ja) 2017-06-15
WO2015115091A1 (ja) 2015-08-06
JP7146031B2 (ja) 2022-10-03
IL266790A (en) 2019-07-31
SI3101032T1 (sl) 2019-02-28
TW202322817A (zh) 2023-06-16
JPWO2015115091A1 (ja) 2017-03-23
LT3466976T (lt) 2021-11-10
TWI796244B (zh) 2023-03-11
LTC3101032I2 (ru) 2022-10-25
MX2016006498A (es) 2016-08-04
KR20160113099A (ko) 2016-09-28
KR20250162923A (ko) 2025-11-19
NZ719202A (en) 2022-02-25
KR102362920B1 (ko) 2022-02-14
EP3466976B1 (en) 2021-09-08
US20200385486A1 (en) 2020-12-10
JP2020097617A (ja) 2020-06-25
TW202237191A (zh) 2022-10-01
TW202237114A (zh) 2022-10-01
HRP20190431T1 (hr) 2019-04-19
US20160333112A1 (en) 2016-11-17
TWI796245B (zh) 2023-03-11
PT4212552T (pt) 2025-01-20
CN105829346A (zh) 2016-08-03
LT4212552T (lt) 2025-01-10
NL301117I2 (nl) 2021-07-29
IL310627A (en) 2024-04-01
EP4464707A2 (en) 2024-11-20
CN105829346B (zh) 2019-08-23
KR20230042126A (ko) 2023-03-27
MX2020010682A (es) 2020-11-06
KR102275925B1 (ko) 2021-07-12
ES2895254T3 (es) 2022-02-18
JP2025138756A (ja) 2025-09-25
DK4212552T3 (da) 2025-02-10
CY2021018I1 (el) 2021-10-15
SMT202500030T1 (it) 2025-03-12
PL3101032T3 (pl) 2019-07-31
KR102314913B1 (ko) 2021-10-19
RU2683780C2 (ru) 2019-04-02
TWI627967B (zh) 2018-07-01
CA2928794C (en) 2019-08-13
SMT201900211T1 (it) 2019-05-10
JP2021169493A (ja) 2021-10-28
EP4212552A1 (en) 2023-07-19
KR20220154251A (ko) 2022-11-21
PH12016500904A1 (en) 2016-07-11
PT3101032T (pt) 2019-04-03
KR20200140932A (ko) 2020-12-16
US20190077880A1 (en) 2019-03-14
EP3101032A4 (en) 2017-09-06
ZA201602802B (en) 2017-09-27
RS62618B1 (sr) 2021-12-31
HRP20211848T1 (hr) 2022-03-04
IL324322A (en) 2025-12-01
TW202525347A (zh) 2025-07-01
HRP20241783T1 (hr) 2025-02-28
LTPA2021515I1 (ru) 2021-08-10
TWI848560B (zh) 2024-07-11
SI3466976T1 (sl) 2021-12-31
EP3101032B1 (en) 2019-01-16
HUE070620T2 (hu) 2025-06-28
TWI661839B (zh) 2019-06-11
KR102510128B1 (ko) 2023-03-14
TW202237113A (zh) 2022-10-01
EP4212552B1 (en) 2024-11-13
TW201934145A (zh) 2019-09-01
KR20210040181A (ko) 2021-04-12
SG11201603960XA (en) 2016-07-28
CA2928794A1 (en) 2015-08-06
PL4212552T3 (pl) 2025-03-17
AU2022203818A1 (en) 2022-06-23
EP3973995A1 (en) 2022-03-30
KR20230113822A (ko) 2023-08-01
TWI796246B (zh) 2023-03-11
LT3101032T (lt) 2019-03-25
MX375930B (es) 2025-03-04
KR102557062B1 (ko) 2023-07-18
CY2021018I2 (el) 2021-10-15
TW202120088A (zh) 2021-06-01
EP3101032A1 (en) 2016-12-07
NL301117I1 (nl) 2021-07-19
RS66412B1 (sr) 2025-02-28
TWI722422B (zh) 2021-03-21
HUE044389T2 (hu) 2019-10-28
CN110464847B (zh) 2024-02-09
JP2019112403A (ja) 2019-07-11
JP2017095457A (ja) 2017-06-01
KR20180122038A (ko) 2018-11-09
KR20210127803A (ko) 2021-10-22
SMT202100659T1 (it) 2022-01-10
JP6046301B1 (ja) 2016-12-14
US10155821B2 (en) 2018-12-18
JP6105183B1 (ja) 2017-03-29
KR102190548B1 (ko) 2020-12-14
KR20220025176A (ko) 2022-03-03
JP5998289B2 (ja) 2016-09-28
JP2024081770A (ja) 2024-06-18
TWI870307B (zh) 2025-01-11
IL310627B1 (en) 2025-12-01
IL278891B1 (en) 2024-02-01
HUE057464T2 (hu) 2022-05-28
JP6665325B2 (ja) 2020-03-13
JP2017036285A (ja) 2017-02-16

Similar Documents

Publication Publication Date Title
RU2019134399A (ru) Конъюгат анти-trop2 антитело-лекарственное средство
KR102880460B1 (ko) 항체에 대한 친화성 물질 및 생체 직교성 관능기를 갖는 화합물 또는 이의 염
IL300540A (en) Preparation method for drug conjugates - antibody against - HER3
HRP20211848T1 (hr) Anti-her2 antitijelo-lijek konjugat
EA200702209A1 (ru) КОНЪЮГАТЫ Aβ ИММУНОГЕННЫХ ПЕПТИДНЫХ НОСИТЕЛЕЙ И СПОСОБЫ ИХ ПОЛУЧЕНИЯ
RU2015119557A (ru) Конъюгаты лекарственное вещество-белок
TWI839287B (zh) 自行穩定之接合劑共軛物
JP2019172710A5 (ru)
RU2015146614A (ru) Конъюгированная вакцина на основе пептида антигена wt1
RU2015119561A (ru) Новые конъюгаты лекарственное вещество-белок
EA202192137A1 (ru) Конъюгат аматоксинового аналога с разветвленными линкерами
JP2017518304A5 (ru)
RU2015129800A (ru) Гидрофильные саморазрушающиеся линкеры и их конъюгаты
RU2016139340A (ru) Коньюгаты "антитело - лекарственное средство" с высокой лекарственной нагрузкой
EA200800300A1 (ru) Конъюгаты иммуногенных пептидных носителей и способы их получения
JP2019500327A5 (ru)
RU2017125050A (ru) Производные fgf21 и их применения
NZ622583A (en) Protein formulations and methods of making same
ES2792598T3 (es) Métodos para preparar conjugados a partir de proteínas que contienen disulfuro
CN108495840A (zh) γ-鹅膏菌素的衍生物
BR112020005605A2 (pt) novos conjugados de amanitina direcionados a psma
RU2016130108A (ru) Конъюгаты полипептидного токсина и антитела, соединенных ковалентной связью
JP2020509010A5 (ru)
WO2011008863A4 (en) Stereoisomer peptides and their polymer conjugates for hiv disease
RU2008112497A (ru) Коньюгат для иммунизации и вакцинации и способ повышения иммуногенности